Archeus Technologies has dosed the first patient in a phase I clinical trial of ARC-706, a yttrium-90 radiopharmaceutical therapy (RPT) designed to augment immune checkpoint inhibition (ICI) in patients with metastatic cancer.
The Madison, WI-based company is developing ARC-706 as a combination strategy for patients receiving validated immunotherapies across multiple oncology indications. The drug leverages Archeus' NM600 tumor-targeting platform, a small-molecule scaffold that targets overexpressed phosphatidylserine in tumor vasculature with the beta-emitter yttrium Y-90 (Y-90). The companion diagnostic PET imaging agent yttrium-86 ARC-166 will be used to guide patient selection and inform dosimetry before treatment, the company said.
In preclinical work, Y-90 ARC-706 demonstrated tumor-selective uptake across multiple ICI-treated cancers, with imaging-guided dosing increasing both response rates to checkpoint inhibitors and the durability of those responses, the company said. The trial is being conducted at the University of Wisconsin’s Carbone Cancer Center.
